Hemerion and its clinical partner Mount Sinai Health System have been nominated for the 8th edition of the Galien MedStartUp Awards, the innovation prize created by the Galien Foundation and Business France.
The Galien Medstartup fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Since 2013, it supports the international development of the most promising French startups, selected by a world-renowned panel, and connecting them with leading American businesses.
Hemerion and Mount Sinai: an ambitious clinical project to fight glioblastoma
Hemerion and Mount Sinai have been nominated in the “Best Collaboration in the MedTech and Digital Health” category, alongside Carthera and Braintale.
Hemerion technology addresses upfront management of newly diagnosed glioblastoma, during surgery, before any adjuvant treatment or drug can be delivered, making its technology a breakthrough innovation that significantly improves both survival and quality of life in patients.
Hemerion technology associates drugs with innovative photonic treatments to selectively kill cancer cells without harming healthy tissue.
The Hemerion-Mount Sinai collaboration mainly aims to sponsor clinical trials to further evaluate the Hemerion technology efficacy against glioblastoma.
Encompassing the Icahn School of Medicine at Mount Sinai and eight hospital campuses in the New York metropolitan area, Mount Sinai is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties, including neurosurgery.
This nomination recognizes the Hemerion / Mount Sinai collaboration as one of the most innovative and promising North American-French projects in the healthcare sector.
A springboard for growth in the USA
The Galien Medstartup Awards have been a real springboard for French businesses, with more than 125 collaborative projects and Franco-American partnerships signed. The Medstartup Days helped raise US$300 million to date and led to more than 400 B2B meetings organized between French firms and North American investors, industrial companies and opinion leaders.
This nomination will allow the Hemerion teams to participate in the Galien Week of innovation and meet with major pharmaceutical, biotech and medtech companies, as well as insurance companies, patient associations and investors to discuss the development of new partnerships.
This recognition paves the way for the development of Hemerion Therapeutics in the United States, which remains the largest healthcare market in the world.